Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 17 April 2017 | By Zachary Brennan
Industry groups BIO and AdvaMed are seeking some changes to the US Food and Drug Administration’s (FDA) guidance on requesting informal input on combination product designations.
Under what’s known as the pre-request for designation (pre-RFD) program, sponsors can ask FDA how their product will be classified (drug, device, biological product or combination product), and which of the agency's three review centers will be responsible for reviewing and regulating the product if it is considered a combination product.
According to draft guidance issued in January, FDA lays out the content and format it expects sponsors to follow when submitting pre-RFDs, noting they are "especially beneficial when the classification of a product or the agency center to which it should be assigned is unclear or in dispute, or if you are contemplating whether or not to pursue a specific configuration or a specific indication."
Under its “general comments,” AdvaMed questions the size of the document package that can be submitted to FDA, noting that “current consensus is that the 15 page limit is often insufficient to provide enough detail to obtain a definitive designation from the Request for Designation process.”
The group representing device companies also said it has “concerns that the primary mode of action (PMOA) is denoted as optional for the Pre-RFD process when the official designation of the product is dependent on the PMOA.”
The group is also pushing FDA to make a determination on the intended use/indications for use rather than the intended claims of a product.
BIO, meanwhile, requests that FDA add metrics in its reports to Congress (that should be made available online in a more real-time basis) to capture response times and the number of extensions.
The group representing biotech interests also seeks clarification on how sponsors may engage with FDA through informal dialogue in this process similar to what is allowed in the current RFD process.
Tags: BIO, AdvaMed, combination product guidance, pre-RFD program
Regulatory Focus newsletters
All the biggest regulatory news and happenings.